Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection (Q36342258)

13 August 2017

Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection (English)

1 reference

13 August 2017

0 references

0 references

0 references

Samuel M Moskowitz

1

1 reference

13 August 2017

Julia C Emerson

2

1 reference

13 August 2017

Sharon McNamara

3

1 reference

13 August 2017

Richard D Shell

4

1 reference

13 August 2017

David M Orenstein

5

1 reference

13 August 2017

Daniel Rosenbluth

6

1 reference

13 August 2017

Marcia F Katz

7

1 reference

13 August 2017

Richard Ahrens

8

1 reference

13 August 2017

Douglas Hornick

9

1 reference

13 August 2017

Patricia M Joseph

10

1 reference

13 August 2017

Ronald L Gibson

11

1 reference

13 August 2017

Moira L Aitken

12

1 reference

13 August 2017

Wade W Benton

13

1 reference

13 August 2017

Jane L Burns

14

1 reference

13 August 2017

20 October 2010

1 reference

13 August 2017

Pediatric Pulmonology

1 reference

13 August 2017

46

1 reference

13 August 2017

184-192

1 reference

13 August 2017

2

1 reference

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

Standardization of Spirometry, 1994 Update. American Thoracic Society

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

Microbiology of sputum from patients at cystic fibrosis centers in the United States

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3479399

Shifting patterns of inhaled antibiotic use in cystic fibrosis

29 June 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21350

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21350

Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21350

Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21350

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21350

Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21350

Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21350

Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21350

Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone

21 January 2018

1 reference

12 December 2020

Multidrug-resistant pulmonary infection in cystic fibrosis--what does 'resistant' mean?

1 reference

12 December 2020

Is there value in susceptibility testing of Pseudomonas aeruginosa causing chronic infection in patients with cystic fibrosis?

1 reference

12 December 2020

A retrospective analysis of biofilm antibiotic susceptibility testing: A better predictor of clinical response in cystic fibrosis exacerbations

1 reference

12 December 2020

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

12 December 2020

Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis

1 reference

12 December 2020

Identifiers

DOI

10.1002/PPUL.21350

1 reference

13 August 2017

1 reference

13 August 2017

1 reference